On October 2, Sanofi SA declined 3.17% overnight, trading at $39.38 per share, with turnover of $490,400. The pullback came immediately after the stock surged 9.4% in the prior session following the company's release of optimistic fiscal year revenue and profit guidance that was projected to exceed market expectations.

The decline is broadly attributed to short-term profit-taking as traders locked in gains from the sharp rally. Meanwhile, ongoing uncertainty surrounding the renegotiation of Sanofi's drug development collaboration with Regeneron Pharmaceuticals added pressure. According to an RBC Capital Markets report, Regeneron needs to secure more favorable economic terms on follow-on products, with investors nearly evenly split on whether updated Dupixent terms alone would suffice or if additional concessions from Sanofi would be required. The unresolved nature of these talks has weighed on sentiment.

Adding to pipeline concerns, Sanofi previously halted clinical development of amlitelimab for moderate-to-severe atopic dermatitis after concluding that accumulated safety and efficacy data did not support further progress. Investors continue to monitor the company's pipeline risk profile ahead of its next earnings report expected on October 30.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)